Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine
Abstract Thyroid cancer (TC) being the common endocrine malignancy is glooming steadily due to its poor prognosis. The treatment strategies of surgery, radiotherapy, and conventional chemotherapy are providing unsatisfactory output. However, combination therapy can negotiate the worse prognosis to t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-12-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-024-01677-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846112445115924480 |
|---|---|
| author | Deepak Gulwani Priyanka Upadhyay Ridhima Goel Vijaya Sarangthem Thoudam Debraj Singh |
| author_facet | Deepak Gulwani Priyanka Upadhyay Ridhima Goel Vijaya Sarangthem Thoudam Debraj Singh |
| author_sort | Deepak Gulwani |
| collection | DOAJ |
| description | Abstract Thyroid cancer (TC) being the common endocrine malignancy is glooming steadily due to its poor prognosis. The treatment strategies of surgery, radiotherapy, and conventional chemotherapy are providing unsatisfactory output. However, combination therapy can negotiate the worse prognosis to the better, where chemoradiotherapy, radiotherapy with surgery, or dual chemotherapeutic drugs are being glorified. Chemotherapy includes the use of doxorubicin or taxanes generally with platinum-based drugs viz. cisplatin or carboplatin that are administered alone or along with multitarget tyrosine kinase inhibitors viz. Lenvatinib, Sorafenib, Sunitinib, Vandetanib, Pyrazolo-pyrimidine compounds, etc., single target tyrosine kinase inhibitors like Dabrafenib plus Trametinib and Vemurafenib against BRAF, Gefitinib against EGFR, Everolimus against mTOR, vascular disruptors like Fosbretabulin, and immunotherapy with viz. Spartalizumab and Pembrolizumab, are anti-PD-1/PD-L1 molecules. Hence, several trials are currently evaluating the possible beneficial role of combinatorial therapy in TC. Since TC is the outcome of multiple genetic alterations, it necessitates targeting the multiple factors in a single shot. These combination strategies for systemically delivering therapeutic drugs seem feasible only with the help of theranostic. To date, nanoparticle-based drug delivery systems (NDDS) have devoted themselves to diagnosis, bioimaging, imaging-assisted surgery, and therapy with high success rates. The ease of handling hybrid technologies is also selectively admirable. However, in this review, we have summarized the sequential progression of chemotherapeutic drugs to NDDS designed for Personalized Medicine (PM) against TC. Personalized medicine is an ever-growing field that will be explored in future discoveries in biomedicine, particularly cancer theranostics. Hence, our review presents a closer view of NDDS as a personalized treatment for TC. We have also discussed the primary challenges facing NDDS in meeting excellence in PM. |
| format | Article |
| id | doaj-art-d41f87d7fc1a47b3b32fe773d603e0ee |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-d41f87d7fc1a47b3b32fe773d603e0ee2024-12-22T12:35:38ZengSpringerDiscover Oncology2730-60112024-12-0115112210.1007/s12672-024-01677-8Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicineDeepak Gulwani0Priyanka Upadhyay1Ridhima Goel2Vijaya Sarangthem3Thoudam Debraj Singh4Department of Medical Oncology Laboratory, All India Institute of Medical SciencesDepartment of Medical Oncology Laboratory, All India Institute of Medical SciencesDepartment of Medical Oncology Laboratory, All India Institute of Medical SciencesDepartment of Pathology, All India Institute of Medical SciencesDepartment of Medical Oncology Laboratory, All India Institute of Medical SciencesAbstract Thyroid cancer (TC) being the common endocrine malignancy is glooming steadily due to its poor prognosis. The treatment strategies of surgery, radiotherapy, and conventional chemotherapy are providing unsatisfactory output. However, combination therapy can negotiate the worse prognosis to the better, where chemoradiotherapy, radiotherapy with surgery, or dual chemotherapeutic drugs are being glorified. Chemotherapy includes the use of doxorubicin or taxanes generally with platinum-based drugs viz. cisplatin or carboplatin that are administered alone or along with multitarget tyrosine kinase inhibitors viz. Lenvatinib, Sorafenib, Sunitinib, Vandetanib, Pyrazolo-pyrimidine compounds, etc., single target tyrosine kinase inhibitors like Dabrafenib plus Trametinib and Vemurafenib against BRAF, Gefitinib against EGFR, Everolimus against mTOR, vascular disruptors like Fosbretabulin, and immunotherapy with viz. Spartalizumab and Pembrolizumab, are anti-PD-1/PD-L1 molecules. Hence, several trials are currently evaluating the possible beneficial role of combinatorial therapy in TC. Since TC is the outcome of multiple genetic alterations, it necessitates targeting the multiple factors in a single shot. These combination strategies for systemically delivering therapeutic drugs seem feasible only with the help of theranostic. To date, nanoparticle-based drug delivery systems (NDDS) have devoted themselves to diagnosis, bioimaging, imaging-assisted surgery, and therapy with high success rates. The ease of handling hybrid technologies is also selectively admirable. However, in this review, we have summarized the sequential progression of chemotherapeutic drugs to NDDS designed for Personalized Medicine (PM) against TC. Personalized medicine is an ever-growing field that will be explored in future discoveries in biomedicine, particularly cancer theranostics. Hence, our review presents a closer view of NDDS as a personalized treatment for TC. We have also discussed the primary challenges facing NDDS in meeting excellence in PM.https://doi.org/10.1007/s12672-024-01677-8Thyroid cancerPersonalized medicineNanotheranosticAnaplastic |
| spellingShingle | Deepak Gulwani Priyanka Upadhyay Ridhima Goel Vijaya Sarangthem Thoudam Debraj Singh Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine Discover Oncology Thyroid cancer Personalized medicine Nanotheranostic Anaplastic |
| title | Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine |
| title_full | Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine |
| title_fullStr | Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine |
| title_full_unstemmed | Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine |
| title_short | Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine |
| title_sort | nanomedicine mediated thyroid cancer diagnosis and treatment an approach from generalized to personalized medicine |
| topic | Thyroid cancer Personalized medicine Nanotheranostic Anaplastic |
| url | https://doi.org/10.1007/s12672-024-01677-8 |
| work_keys_str_mv | AT deepakgulwani nanomedicinemediatedthyroidcancerdiagnosisandtreatmentanapproachfromgeneralizedtopersonalizedmedicine AT priyankaupadhyay nanomedicinemediatedthyroidcancerdiagnosisandtreatmentanapproachfromgeneralizedtopersonalizedmedicine AT ridhimagoel nanomedicinemediatedthyroidcancerdiagnosisandtreatmentanapproachfromgeneralizedtopersonalizedmedicine AT vijayasarangthem nanomedicinemediatedthyroidcancerdiagnosisandtreatmentanapproachfromgeneralizedtopersonalizedmedicine AT thoudamdebrajsingh nanomedicinemediatedthyroidcancerdiagnosisandtreatmentanapproachfromgeneralizedtopersonalizedmedicine |